Alumni raised $1.45B in 2022 - Download Free Report Now

ChanRx

Small molecule drug candidates directed at ion channel targets to repurpose existing therapies for atrial fibrillation.

Start Free Trial
Claim Company Profile

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of ChanRx plus 5517 other startups.

Start Free 7 Day Trial Now

Learn More About ChanRx

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups

More

Companies We Work With

  • 0-Minnetronix.jpg
  • 1-jnj.png
  • 2-medtronic.png
  • 3-abbott.png
  • 4-baxter.png
  • 7-bostonscientific.png
  • 8-bd.png
  • 9-smithnephew.png
  • 10-stryker.png
  • 33m.png
  • allergan.jpg
  • bain.jpg
  • bbraun.png
  • beckmancoulter.png
  • cardinal.png
  • depuysynthes.png
  • drager.png
  • edwardslifesciences.png
  • ethicon.png
  • ge.png
  • gore.png
  • hospira.png
  • jlabs.jpg
  • kimberlyclark.png
  • merck.jpg
  • olympus.png
  • orthofix.png
  • philips.png
  • sanofigenzyme.png
  • teleflex.jpg
  • terumo.png
  • zimmerbiomet.png